

September 27, 2017

To members of the press

Nichi-Iko Pharmaceutical Co., Ltd.
Yakuhan Pharmaceutical Co., Ltd.
AYUMI Pharmaceutical Corporation

About Marketing Approval for Infliximab BS for I.V. Infusion 100mg "AYUMI"

We are pleased to announce that Yakuhan Pharmaceutical Co., Ltd. (Head office: Kitahiroshima-shi, Hokkaido; Representative Director: Toru Kanazawa), the 100% subsidiary of Nichi-Iko Pharmaceutical Co., Ltd. (Head office: Toyama-shi, Toyama Prefecture; President & CEO: Yuichi Tamura), received manufacturing and marketing approval for Infliximab BS for I.V. Infusion 100mg "AYUMI".

As previously notified, this drug will be marketed by AYUMI Pharmaceutical Corporation (Head office: Chuo-ku, Tokyo; President: Hikaru Ouchi) in accordance with the Licensing Agreement for Marketing Rights concluded with AYUMI Pharmaceutical Corporation.

End

Contacts for Inquiries	
AYUMI Pharmaceutical Corporation Corporate Planning Department Tel: 03-6264-3525	Nichi-Iko Pharmaceutical Co., Ltd. President Office Tel: 076-442-7026